

Block listing Interim Review

1 June 2017 15:00 BST

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 1 JUNE 2017

Name of applicant: ASTRAZENECA PLC

Name of scheme: ASTRAZENECA SHARE OPTION PLAN;

ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE

OPTION SCHEME

Period of return: From: 1 DECEMBER To: 31 MAY 2017

2016

3,587,335

Balance of unallotted securities under scheme(s) from previous return:

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has

been applied for):

Less: Number of securities issued/allotted

under scheme(s) during period (see

LR3.5.7G):

Equals: Balance under scheme(s) not yet

issued/allotted at end of period:

695,679

2,891,656

Name of contact:

CAMILLA WISEMAN
Telephone number of contact:

020 3749 5000

About AstraZeneca

Media Relations

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
|---|--|--|
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | | |
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| | | 177 200 170 01 12 |
| Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
| | Finance, Fixed Income, M&A Oncology | |
| Craig Marks | | +44 7881 615 764 |
| Craig Marks Henry Wheeler | Oncology | +44 7881 615 764 +44 203 749 5797 |
| Craig Marks Henry Wheeler Mitchell Chan | Oncology Oncology Cardiovascular & Metabolic | +44 7881 615 764 +44 203 749 5797 +1 240 477 3771 |
| Craig Marks Henry Wheeler Mitchell Chan Lindsey Trickett | Oncology Oncology Cardiovascular & Metabolic Diseases | +44 7881 615 764 +44 203 749 5797 +1 240 477 3771 +1 240 543 7970 |

Adrian Kemp

Company Secretary, AstraZeneca PLC